论文部分内容阅读
为了防止今冬明春SARS的再度出现,美国雅培制药推出和发售由德国Artus GmbH生物技术公司开发和生产的诊断测试方法,以帮助亚洲国家的政府实验室检测怀疑导致SARS的冠状病毒。 这种检测方法基于被称为实时聚合酶链式反应(PCR)的高灵敏度科技,能够立即检测出病体样本中的微小数量的病毒。这种检测方法将在Applied Biosystems公司的ABI Prism 7000序列测试系统上运行,以检测在病体样本上的病毒核酸序列并确定其数量。ABI Prism 7000序列测试系统被广泛应用在
To prevent the recurrence of SARS this winter and next spring, Abbott Laboratories (USA) has introduced and distributed a diagnostic test developed and produced by Artus GmbH, a biotechnology company in Germany, to help government laboratories in Asian countries detect coronavirus suspected of causing SARS. This detection method is based on the highly sensitive technology known as real-time polymerase chain reaction (PCR), which allows the immediate detection of a small number of viruses in a patient’s sample. This assay will run on the Applied Biosystems ABI Prism 7000 Sequencing System to detect and determine the viral nucleic acid sequences on the patient’s sample. The ABI Prism 7000 Sequence Test System is widely used